Ceftaroline fosamil
DrugSingle dose of 15 mg/kg (up to 600 mg) by intravenous infusion
NCT Number: NCT01298843
The purpose of this study is to assess blood levels of Ceftaroline fosamil in children.
Looking for future studies?
Notify MeUp to 11 year
All sexes
Interventional
Phase 4
Investigational Site, Phoenix, Arizona, United States
To characterize single dose pharmacokinetics of Ceftaroline fosamil in children.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects must meet the following inclusion criteria:
Exclusion criteria
Subjects must NOT meet any of the following exclusion criteria:
Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
Time frame: Up to 5 days
This study has 3 primary outcome measures: plasma concentration of ceftaroline fosamil and its metabolites from blood samples after a single dose; PK profile of ceftaroline, and safety, where number of subjects with serious and non-serious adverse events and type of frequency of adverse events will be reported.
Forest Laboratories
Industry
Pharmacokinetics of a Single Dose of Ceftaroline Fosamil in Children Ages Birth to Younger Than 12 Years With Suspected or Confirmed Infection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02505386
Infections
Bordeaux, France
View Trial DetailsNCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT02231879
Agammaglobulinemia, Agranulocytosis
Bethesda, Maryland, United States
View Trial DetailsNCT05180110
Infections, Inflammation
Edinburgh, United Kingdom
View Trial Details